Clinical trials
Respiratory Tract Diseases trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 2 |
| 2017 | 6 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Terminated | 5 |
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 4 |
| Blueprint Medicines Corporation | 2 |
| Eli Lilly and Company | 2 |
| Pfizer | 2 |
| Revolution Medicines, Inc. | 2 |
| United Therapeutics | 2 |
| AVEO Pharmaceuticals, Inc. | 1 |
| Alpha Biopharma (Jiangsu) Co., Ltd. | 1 |
| Bellus Health Inc. - a GSK company | 1 |
| Celgene | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Respiratory Tract Diseases | 23 |
| Lung Diseases | 19 |
| Carcinoma, Non-Small-Cell Lung | 11 |
| Lung Neoplasms | 11 |
| Neoplasms | 10 |
| Neoplasms by Site | 10 |
| Respiratory Tract Neoplasms | 10 |
| Bronchial Neoplasms | 9 |
| Thoracic Neoplasms | 9 |
| Carcinoma, Bronchogenic | 7 |
Trials
Showing 51 to 23 of 23. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.